Charalampos S. Floudas

1.9k total citations · 2 hit papers
64 papers, 1.1k citations indexed

About

Charalampos S. Floudas is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charalampos S. Floudas has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 13 papers in Surgery and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charalampos S. Floudas's work include Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (10 papers) and Cancer Research and Treatments (10 papers). Charalampos S. Floudas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (10 papers) and Cancer Research and Treatments (10 papers). Charalampos S. Floudas collaborates with scholars based in United States, Greece and Italy. Charalampos S. Floudas's co-authors include Abhinav Chandra, Vivek Kumar, Neha Chaudhary, Mohit Garg, Parita Soni, James L. Gulley, Dara Bracken‐Clarke, Fatima Karzai, Giovanni Maria Iannantuono and Tim F. Greten and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Charalampos S. Floudas

57 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

2017 465 citations Charalampos S. Floudas et al. profile →
Matching patients to clinical trials with large language models

2024 78 citations Qiao Jin, Charalampos S. Floudas et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charalampos S. Floudas United States	14	677	242	200	174	158	64	1.1k
Douglas Zippel Israel	17	561 0.8×	373 1.5×	102 0.5×	361 2.1×	117 0.7×	56	1.3k
Dipesh Uprety United States	15	484 0.7×	64 0.3×	377 1.9×	74 0.4×	313 2.0×	71	1.0k
Arsela Prelaj Italy	18	677 1.0×	130 0.5×	521 2.6×	59 0.3×	169 1.1×	82	1.0k
Sagar Rakshit United States	15	686 1.0×	118 0.5×	579 2.9×	97 0.6×	89 0.6×	26	1.2k
Yukio Iwashita Japan	20	536 0.8×	231 1.0×	289 1.4×	512 2.9×	181 1.1×	79	1.3k
Marjorie G. Zauderer United States	27	759 1.1×	145 0.6×	1.2k 6.1×	109 0.6×	365 2.3×	104	2.3k
Nolwenn Le Stang France	17	352 0.5×	70 0.3×	628 3.1×	94 0.5×	107 0.7×	28	1.1k
Haider Mahdi United States	22	509 0.8×	148 0.6×	157 0.8×	387 2.2×	274 1.7×	121	1.7k
Won‐Suk Lee South Korea	20	717 1.1×	104 0.4×	283 1.4×	639 3.7×	145 0.9×	46	1.4k
Lin‐Quan Tang China	20	631 0.9×	78 0.3×	406 2.0×	411 2.4×	247 1.6×	98	1.4k

Countries citing papers authored by Charalampos S. Floudas

Since Specialization

Citations

This map shows the geographic impact of Charalampos S. Floudas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charalampos S. Floudas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charalampos S. Floudas more than expected).

Fields of papers citing papers by Charalampos S. Floudas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charalampos S. Floudas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charalampos S. Floudas. The network helps show where Charalampos S. Floudas may publish in the future.

Co-authorship network of co-authors of Charalampos S. Floudas

This figure shows the co-authorship network connecting the top 25 collaborators of Charalampos S. Floudas. A scholar is included among the top collaborators of Charalampos S. Floudas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charalampos S. Floudas. Charalampos S. Floudas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bracken‐Clarke, Dara, Danielle M. Pastor, Jennifer L. Marté, et al.. (2026). The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer. The Oncologist. 31(3).

Floudas, Charalampos S., Siranush Sarkizova, Michele Ceccarelli, & Wei Zheng. (2025). Leveraging mRNA technology for antigen based immuno-oncology therapies. Journal for ImmunoTherapy of Cancer. 13(1). e010569–e010569. 7 indexed citations

Redman, Jason M., Renee N. Donahue, Jennifer L. Marté, et al.. (2025). Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. The Oncologist. 30(3).

Floudas, Charalampos S., Meghali Goswami, Renee N. Donahue, et al.. (2025). Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers. JAMA Oncology. 11(4). 394–394. 10 indexed citations

Thakkar, Punam, Joseph Goodman, Arjun S. Joshi, et al.. (2024). Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation. Cancer Medicine. 13(7). e7146–e7146. 1 indexed citations

Xue, Elisabetta, Dara Bracken‐Clarke, Evrim Türkbey, et al.. (2024). Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3183–TPS3183. 1 indexed citations

Bracken‐Clarke, Dara, Clint Allen, Elisabetta Xue, et al.. (2024). Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS6124–TPS6124.

Steuer, Conor, Daniel Lubin, Tolulope Adeyelu, et al.. (2024). Genomic and immune profiling of rare non-squamous sinonasal tumors.. Journal of Clinical Oncology. 42(16_suppl). e18008–e18008. 1 indexed citations

Haque, Fahmida, Jorge A. Carrasquillo, Evrim Türkbey, et al.. (2024). An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET/CT. EJNMMI Research. 14(1). 103–103. 4 indexed citations

10.

Fantini, Massimo, Kwong Y. Tsang, Kevin C. Conlon, et al.. (2024). Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2530–2530. 1 indexed citations

11.

Jin, Qiao, Charalampos S. Floudas, Fangyuan Chen, et al.. (2024). Matching patients to clinical trials with large language models. Nature Communications. 15(1). 9074–9074. 78 indexed citations breakdown →

12.

Xue, Elisabetta, Dara Bracken‐Clarke, Giovanni Maria Iannantuono, et al.. (2024). Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard. Journal of Medical Internet Research. 26. e54758–e54758. 10 indexed citations

13.

Iannantuono, Giovanni Maria, Dara Bracken‐Clarke, Fatima Karzai, et al.. (2024). Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. The Oncologist. 29(5). 407–414. 23 indexed citations

14.

Oliver, Jeremie D., Fábio R. Faucz, Charalampos S. Floudas, et al.. (2024). Spatial Transcriptomic Analysis of Pituitary Corticotroph Tumors. Journal of the Endocrine Society. 8(6). bvae064–bvae064. 2 indexed citations

15.

Karzai, Fatima, et al.. (2024). Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. JNCI Journal of the National Cancer Institute. 116(7). 1063–1071. 5 indexed citations

16.

Florou, Vaia, Charalampos S. Floudas, Asaf Maoz, et al.. (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for ImmunoTherapy of Cancer. 11(8). e007440–e007440. 9 indexed citations

17.

Gatti‐Mays, Margaret E., Nicholas Tschernia, Julius Strauss, et al.. (2023). A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. The Oncologist. 28(4). 364–e217. 9 indexed citations

18.

Iannantuono, Giovanni Maria, Charalampos S. Floudas, Hyoyoung Choo‐Wosoba, et al.. (2023). Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treatment Reviews. 120. 102623–102623. 15 indexed citations

19.

Bilušić, Marijo, Sheri McMahon, Ravi A. Madan, et al.. (2021). Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer. 9(3). e002374–e002374. 43 indexed citations

20.

Moyssakis, Ioannis, Elias Gialafos, Nikolaοs Tentolouris, et al.. (2008). Impaired aortic elastic properties in patients with systemic sarcoidosis. European Journal of Clinical Investigation. 38(2). 82–89. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact